Inhalable insulin for diabetes wins FDA approval

imagesThe Food and Drug Administration on Friday approved a long-delayed inhalable diabetes medication to help patients control their blood sugar levels during meals.

The FDA cleared MannKind Corp.’s drug Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes that affects more than 25 million Americans. The approval decision comes more than three years after the agency first asked MannKind to run additional clinical studies on the drug.

Diabetes is a chronic condition in which the body either does not make enough insulin to break down the sugar in foods or uses insulin inefficiently. It can lead to blindness, strokes, heart disease or death. In Type 2 diabetes, the most common form of the disease, the body does not use insulin properly. Type 1 diabetes is usually diagnosed in children and young adults. In those cases, the body does not produce insulin.

Afrezza, an insulin powder, comes in a single-use cartridge and is designed to be inhaled at the start of a meal or within 20 minutes of starting. MannKind has said patients using the drug can achieve peak insulin levels within 12 to 15 minutes. That compares to a wait time of an hour and a half or more after patients inject insulin.

The FDA said in its approval announcement that Afrezza is not a substitute for long-acting insulin and is a new option for controlling insulin levels during meals.

The FDA approved the drug with a boxed warning — the strongest type — indicating that the drug should not be used in patients with chronic lung diseases, such as asthma, due to reports of breathing spasms.

Demand for diabetes treatments are surging globally as the prevalence of obesity explodes. Roughly 347 million people worldwide have the disease, according to the World Health Organization.

New effort to fight diabetes in Sonoma County

story

Sonoma County medical providers are taking aggressive steps to deal with the high rate of patients with diabetes admitted to local hospitals, a trend that is said to be driving up hospital costs.

In Sonoma County, patients with diabetes account for almost 26 percent of all local hospital admissions, according to a recent UCLA analysis of 2011 hospital patient discharge data. That’s a total of 7,459 hospital admissions.

The added cost of hospital care is estimated at $16.4 million, according to the study, which was conducted by the UCLA Center for Health Policy Research with support from the California Center for Public Health Advocacy.

“We are very concerned about the epidemic of diabetes and the toll that it takes on individuals and the system that cares for them,” said Karen Holbrook, the county’s deputy public health officer.

Holbrook said diabetic patients who are admitted to local hospitals pose more medical complications than those who are not diabetic and often require more tests and treatments. Severe diabetes often results in serious medical conditions such as liver disease and kidney failure, she said.

According to the UCLA study, 31 percent of the state’s hospitalized patients 35 years or older, the age group that accounts for most hospitalizations, had diabetes. The study estimated that the added cost to hospitals in California was $1.6 billion. Hospital stays for diabetic patients in the state cost an average of $2,200 more than for non-diabetic patients, according to the study.

The study’s authors pointed out that 75 percent of this care is covered by Medicare and Medi-Cal, the state’s Medicaid program. Medi-Cal alone pays $254 million in added costs for diabetic patients.

The Tour de Cure event hosted by the American Diabetes Association of Northeast Ohio has already raised $250,000 for diabetes research

1403982570000-tour-de-cure.jpg

CUYAHOGA FALLS — The Tour de Cure event hosted by the American Diabetes Association of Northeast Ohio has already raised $250,000 for diabetes research in the region, according to Melissa Sutton, the event manager.

The annual event leads riders through a bike route as long as 100 miles. However, riders could also bike shorter distances.

The Saturday ride kicked off at the Cuyahoga Valley Christian Academy on Wyoga Lake Rd. in Cuyahoga Falls.

Participants could also enjoy on-site activities geared towards fun and information about diabetes.

Sutton, who has lived with type one diabetes since she was 9-years-old, says she hopes the ride will combat the stigma the disease faces. “My pancreas stopped working and there’s not a darn thing I can do about it,” Sutton tells Channel 3’s Hilary Golston. “It stops working. So I take it particularly personally when people think it’s a lifestyle disease.”

According to the ADA, 330,000 people have diabetes in Northeast Ohio. “Red riders” or those living with the disease donned red shirts to denote they have diabetes and are participating in the race.

Riders were asked to raise at least $200 to participate, but some raised much more. 11-year-old Gabe Grizwald was able to rake in $2,000. He’s also living with type one diabetes. “I ride for diabetes because it’s just a horrible disease to have and it’s really just changed my life and I think it helps so much when people ride for us and raise money and it really could lead to a cure,” Grizwald tells Golston.

Brian Travalik is Tour de Cure’s red rider ambassador. Decked out in a tutu for flare, he not only lives with diabetes, but represents the so-called “red riders.” Red riders are those who have diabetes and are also participating in Tour de Cure. “It’s a chance to be honored as a hero,” Travalik said. “To see other people with diabetes, it’s a good feeling to be around that comradery of other people that are dealing with that same disease.”

It’s not too late to donate to the cause. You can head over to http://main.diabetes.org/site/TR?fr_id=9375&pg=pfind to give.

 

Human gut cells turned into insulin producers may treat diabetes

Scientists have converted human gut cells into insulin producers by turning off a single gene in an experiment that suggests a novel way forward in treating diabetes.

Using a miniature model of the human intestine, only a few millimeters in size and made from stem cells, the scientists deactivated a gene in the cells tied to metabolic regulation called FOXO1. Once disabled, the cells began producing insulin.

The method, described Monday in the journal Nature Communications, raises the possibility of replacing insulin- making pancreatic beta cells lost in diabetics by using a drug to retrain patients’ existing cells. While progress has been made in generating beta cells from stem cells, the method hasn’t yet produced ones with all the needed functions, said Domenico Accili, the study’s lead author. Plus, such cells would require transplantation.

“We provided a proof of principle that we can do this in human tissues and are also very excited that there is a single identifiable target to trigger this process,” Accili, professor of medicine at Columbia University’s Naomi Berrie Diabetes Research Center in New York, said in an interview. “This is what the pharmaceutical industry is interested in — make a chemical and do what we did in test tubes to administer to persons with diabetes and teach their gut cells to become beta cells.”

The results build on research two years ago by Accili and his team that first tested the approach in mice, successfully converting gut cells into insulin-making cells. In the human cell experiment, the gut cells started releasing insulin after seven days and only in response to insulin.

Now that Accili and his team have shown it works in human cells, their next step is to develop a drug to test in people. Accili said it’s possible that there could be a compound for clinical trials in a year or two.

Diabetes, which results when the body doesn’t use insulin properly or doesn’t make the hormone, is the seventh-leading cause of death in the U.S. Insulin is a hormone secreted by the pancreas that helps the body control blood sugar.

Destruction of insulin-making beta cells in the pancreas is the central feature of Type 1 and Type 2 diabetes. In Type 1 diabetics, the pancreas are destroyed by the immune system and don’t produce insulin. In Type 2, in which the body doesn’t use insulin properly, beta cells become progressively dysfunctional.

One advantage to this experimental approach is that the gastrointestinal tract is partly protected from attack by the immune system, making gut cells less susceptible to destruction, Accili said.

A treatment for diabetes that doesn’t require daily insulin injections would change the treatment landscape for the 29 million diabetics in the U.S. However, it’s likely that any potential drug would first be evaluated for Type 2 diabetes, because of concerns of testing in Type 1 diabetics going without insulin injections, he said.

“The work is a laser-like focus on turning this into a treatment,” Accili said. “We follow 3,000 patients with Type 1 at the Berrie Center alone. That’s our main goal.”

Collaborations with drugmakers are already under way, Accili said, though he declined to name companies.

British drugmaker AstraZeneca Plc helped fund the research, with the National Institutes of Health, the Manpei Suzuki Diabetes Foundation, the Swedish Society for Medical Research, the Japan Society for the Promotion of Science, the JPB Foundation and the Brehm Coalition.

June 30, 2014 ~ Ginger Vieira, Dealing with Diabetes Burnout

photo2Ginger Vieira

Author of Your Diabetes Science Experiment and Emotional Eating with Diabetes, Ginger Vieira has lived with Type 1 diabetes and Celiac disease since 1999, and fibromyalgia since early 2014. Today, she is an avid freelance writer and motivational speaker with a background as a certified cognitive coach, personal trainer, and Ashtanga yoga instructor specializing in coaching people with diabetes. She creates diabetes video blogs at her YouTube Channel and produces regular freelance content for various diabetes websites including DiabetesDaily.com and ASweetLife.org. In 2009 and 2010, Ginger set 15 records in drug-tested powerlifting with her best lifts including a 308 lb deadlift, 190 lb. bench press, and a 265 lb. squat. Today, she lives in Vermont with three dogs and her fella. Living-in-progress.com

index

Listen to the latest broadcast of Diabetes Living Today®:  June 3o, 2014 ~ Ginger Vieira on Dealing with Diabetes Burnout.

 

March 31, 2014 ~ Medtronic Insulin Pump Therapy and CGM with Dr. Francine R. Kaufman

Photo_FrancineKaufman

 

FRANCINE R. KAUFMAN, M.D.

Chief Medical Officer and Vice President, Global Medical,

Clinical & Health Affairs, Medtronic Diabetes

Emeritus Professor of Pediatrics and Communications at USC

The Center for Diabetes, Endocrinology & Metabolism

Francine Ratner Kaufman, M.D. has had a 30 year distinguished careerin diabetes care, research and advocacy.  In 2009, she stepped down as director of the Comprehensive Childhood Diabetes Center, and head of the Center for Endocrinology, Diabetes and Metabolism at Childrens Hospital Los Angeles to become Chief Medical Officer and VP of Global Clinical, Medical and Health affairs at Medtronic Diabetes (Northridge, CA).

 

Dr. Kaufman is also a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California, and an attending physician at Childrens Hospital Los Angeles.

Dr. Kaufman has published more than 200 peer-reviewed and invited publications. She is the author of more than 30 books or book chapters. In 2008, she edited the 5th edition of the ADA’s the Medical Management of Type 1 Diabetes.  In 2005 her book, Diabesity, was published by Bantam. Diabesity explores the ravages of the obesity and diabetes epidemics as they spread across the globe. Dr. Kaufman was chair of the National Institutes of Health funded Studies to Treat (the TODAY Trial) and Prevent (the HEALTHY Trial) Type 2 Diabetes in Youth (STOPP-T2). She was a principal investigator of TrialNet, a multinational consortium evaluating ways to prevent type 1 diabetes, funded by the National Institutes of Health (NIH).  She has received many awards and honors, including the LA City Council for promoting youth physical fitness (2004), from the State of California for her role in banning sodas from Los Angeles Unified School District (2003), and from the American Diabetes Association (ADA), Juvenile Diabetes Research Foundation (JDRF), European Association for the Study of Diabetes (EASD), Partners in Care, Starbright Foundation, amongst others.

In 2009, Dr. Kaufman was elected to membership in the Advisory Council of the Diabetes Branch of the NIH. In 2007, she filmed a documentary for Discovery Health on the global diabetes epidemic which was aired around the world on World Diabetes Day, November 14, 2007. Also in 2007, Dr. Kaufman was Co-Chair of the Diabetes Work Group for the Department of Health Services of the State of California to recommend diabetes treatment and prevention strategies for the Medicaid population.  In 2005, she was elected Membership in the Institute of Medicine.  Dr. Kaufman was national president of the American Diabetes Association in 2002-03.  She was elected to AOA Medical Honorary Society. She was also president of Shaping America’s Health, chair of the National Diabetes Education Program, and served as chair of the Youth Consultative Section of the International Diabetes Federation.

Listen to the latest broadcast of Diabetes Living Today®:  March 21, 2014 ~ Medtronic Insulin Pump Therapy and CGM with Dr. Francine R. Kaufman

Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S.

– First FDA Cleared Blood Glucose Meter that Connects Directly to iPhone® and iPod touch® – – Available at Apple® Retail Stores and Walgreens Nationwide, Online at Apple.com, Walgreens.com and through Diabetic Care Services – – Recipient of Two Design Awards for Outstanding Product Design –

BRIDGEWATER, N.J., May 2, 2012 /PRNewswire via COMTEX/ — Sanofi US announced today that the iBGStar® Blood Glucose Monitoring System, consisting of the iBGStar® blood glucose meter and iBGStar® Diabetes Manager App, is commercially available in the U.S. iBGStar® is the first Food and Drug Administration (FDA) cleared blood glucose meter that directly connects to the iPhone® and iPod touch®, offering accurate blood glucose monitoring that seamlessly integrates into the lives of people with diabetes. iBGStar® is available for purchase at Apple® Retail Stores and all Walgreens stores nationwide, online at Apple.com, Walgreens.com and through Diabetic Care Services.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/46108-sanofi-ibgstar-blood-glucose-monitoring-system

“Many people with diabetes today rely both on their iPhone® or iPod touch® and blood glucose monitors as important parts of their daily lives,” said Naina Sinha, MD, an in-patient diabetes attending physician and assistant professor of medicine at a leading academic medical center and university in New York City. “By combining these two essential tools, iBGStar® makes it possible to provide blood glucose tracking, monitoring and reporting together in a new way.”

About iBGStar®When iBGStar® is directly connected to an iPhone® or iPod touch® and used with the iBGStar® Diabetes Manager App, blood glucose results are presented on the Multi-Touch display quickly after monitoring.

iBGStar® can also be used independently to measure blood glucose levels; results can be synchronized later to an iPhone® or iPod touch®. iBGStar® and BGStar® Blood Glucose Test Strips, which are used with iBGStar®, are available at all Walgreens stores nationwide and online at Walgreens.com and through Diabetic Care Services. These test strips may be covered under certain health insurance plans so individuals should check directly with their provider.

The iBGStar® Diabetes Manager App has a range of features and multiple views for analyzing glucose patterns on-the-go. Visual graphs and statistics can help people record and track their readings, carbohydrate intake, insulin doses (if taking insulin) and more. Color-coded scorecards show individual monitoring results for easy identification of high or low blood glucose levels. A ‘share’ function allows specific data to be sent via e-mail to caregivers and/or healthcare teams. The iBGStar® Diabetes Manager App is available for free from the App Store on iPhone® and iPod touch® or at www.itunes.com/appstore .

“Sanofi is pleased to launch iBGStar®, which expands our diabetes portfolio as we pursue comprehensive disease management offerings and further illustrates our commitment to developing innovative solutions that help improve the lives of people with diabetes,” commented Dennis Urbaniak, Vice President, Head of U.S. Diabetes, Sanofi US. “The iBGStar® Blood Glucose Monitoring System will help people living with diabetes check their blood sugar and communicate with their healthcare teams, using mobile technologies that have become central to so many people’s lives.”

In March 2010, Sanofi and AgaMatrix signed an agreement for the development, supply and commercialization of Blood Glucose Monitoring solutions. iBGStar® is a result of this agreement.

iBGStar® received the Good Design(TM) Award in 2011 for outstanding product design in the medical category from the Chicago Athenaeum of Architecture and Design and the European Centre for Architecture Art Design and Urban Studies. Additionally, iBGStar® received the red dot design award in 2011 for outstanding product design in the life science and medicine category. The red dot design award is one of the most renowned international design competitions ( www.red-dot.de/presse ), with almost 14,000 entries from 68 countries in 2010 alone. Winners are considered to be the best design in the industry worldwide.

Apple®, iPhone® and iPod touch® are trademarks of Apple Inc, registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Content purchased from the iTunes Store is for personal lawful use only. Don’t steal music.

For more information, visit www.ibgstar.us .

About the Sanofi Diabetes DivisionSanofi strives to help people manage the complex challenges of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insight that comes from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices, including innovative blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes. Investigational compounds in the pipeline include an injectable GLP-1 agonist being studied as a single agent, in combination with basal insulin, and/or in combination with oral antidiabetic agents.

Important InformationThe iBGStar® meter and lancing device are for single patient use. Do not share them with anyone including other family members. Do not use on multiple patients. All parts of the kit are considered biohazardous and can potentially transmit infectious diseases, even after you have performed cleaning and disinfection.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris /quotes/zigman/187275 FR:SAN +0.97% and in New York /quotes/zigman/307926/quotes/nls/sny SNY +0.16% .

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.

Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

US.BGM.12.02.076

SOURCE Sanofi US

Copyright (C) 2012 PR Newswire. All rights reserved

 

Telcare’s Wireless-Enabled Blood Glucose Monitoring System Wins 2012 Gold Edison Award

Telcare’s New Diabetes Care Management Device Recognized As Best New Science and Medical Online Tool/App

New York, NY (PRWEB) April 27, 2012

Telcare’s wireless enabled blood glucose monitoring system received the 2012 Gold Edison Award for the best new medical and science online tool and app. Today marks the 25th annual Edison Awards competition, which honors the year’s most innovative products, services and business leaders in the world.

Telcare’s FDA-cleared device, introduced in February 2012, wirelessly communicates critical information to diabetes patients, doctors, caregivers and iPhones. It’s the first blood glucose monitor that uses cellular communication to instantly transmit a patient’s readings to a private online database, which can be accessed by the patient or – with permission – by a doctor, caregiver or family member. It tracks results and can spot potential problems and transmits real-time feedback.

“It’s a great honor for Telcare to receive Edison’s top award for innovation,” said Telcare CEO Dr. Jonathan Javitt. “Edison searches for the latest cutting-edge devices and we believe Telcare’s wireless-enabled blood glucose monitor has the capability to transform the lives of 28 million Americans with diabetes.”

Telcare’s blood glucose monitoring system includes Diabetes Pal, currently the highest rated diabetes smartphone app. Diabetes Pal works seamlessly with the Telcare meter to enable family members of people with diabetes to view results in real time and to provide Telcare meter users a diabetes-focused social networking experience. Telcare has chosen to distribute Diabetes Pal at no charge via the Apple iTunes store (and soon via the Google app store) so that people may use it even without purchasing the Telcare system.

“By incorporating wireless communication, social networking, and best practices in health IT, Telcare has brought the monitoring of diabetes into the 21st century for 28 million Americans, their caregivers, and their loved ones,” Dr. Javitt added.

Each year the Edison Awards recognize the world’s most significant innovations. Past winners include Apple for the iPad, Amazon for the Kindle II, and Nintendo for WiiFit. Once again, the 2012 awards drew a group of competitors.

“The Telcare Blood Glucose Monitoring System is an excellent example of an innovative product that reflects the rich tradition of the Edison Awards,” said Thomas Stat, Chairman of the Edison Awards Steering Committee. “By awarding Telcare with the Edison Gold Medal, we have recognized this wireless system as a significant step forward for 28 million diabetics in this country as they pursue healthier, more meaningful lives.”

Telcare was also recently named to Gartner’s list of “Cool Vendors.” Gartner’s analysts praised Telcare’s system for “getting the technology right” and providing “effective solutions” for diabetes care.” According to Gartner, “This is the same technology that made Kindle the book reader that grandma loves.”

About Telcare
Telcare, Inc. uses cellular technology and social networking to bridge the last mile between patients with diabetes, their caregivers, and their families in order to transform the care of chronic illness. Telcare has been awarded First Place prizes in the categories of Health, Wellness and Fitness Application and Health Enterprise Solution by CTIA, been named the MEDTEC startup of the year, and been named one of the top 12 products of 2012 by the Edison Awards. In addition to directly reducing cost of care by improving outcomes and preventing complications, Telcare creates an ecosystem of care that enables people with diabetes to better care for their condition. For more information, visit www.telcare.com.

About the Edison Awards and Edison Universe
The Edison Awards were established in 1987 to honor and advance Thomas Edison’s wideranging contributions to technology and consumer products, as well as to inspire continued innovation in the world. In addition to the Edison Achievement Award, the organization also recognizes new product and service innovations through its annual Edison Awards and Edison Green Awards and, through its non-profit organization, Edison Universe, supports future innovators and fosters future innovation. For more information, visit www.edisonawards.com.

‘Inadequate’ NHS diabetes care causing patients ‘harm’ By Mike Tighe

People with diabetes need to check their blood sugar levels.

NHS diabetes care is ‘inadequate’ and some patients come to further harm due to poor care in hospital, a leading specialist says.

Dr Gerry Rayman, national clinical lead for inpatient diabetes, warned many hospitals had no specialist diabetes nurse.

He said many hospital patients had diabetes, and called the situation ‘quite alarming’.

The Department of Health said work was under way to improve care standards.

Speaking on BBC Radio 4’s You and Yours, Dr Rayman, head of the diabetes service at Ipswich Hospital NHS Trust, said: “We know that one in three hospitals don’t have a specialist diabetes nurse, which is really quite alarming when we know that one in six people in hospital have diabetes.

“Unfortunately, many people in hospital with diabetes do come to harm as a result of, I’m afraid to say, inadequate care in hospital.”

Diabetes accounts for 11% of all NHS inpatient expenditure, and costs the service around £23.7bn last year, a figure projected to increase to just under £40bn by 2035.

Two types

Diabetes complications

  • Diabetes that is not controlled can cause many serious long-term problems.
  • Excess glucose (sugar) in the blood can damage the blood vessels, contributing to heart disease, strokes, kidney disease, impotence and nerve damage.
  • Uncontrolled diabetes is the most common cause of blindness in people of working age.
  • People with diabetes are also 15% more likely to have an amputation than people without the condition.

In Type 2 diabetes, not enough insulin is produced or the insulin that is made by the body does not work properly.

It tends to affect people as they get older and usually appears after the age of 40, but increasingly is seen in younger, overweight people. It accounts for 90% of all cases.

Type 1 diabetes, a condition which usually means insulin cannot be produced at all, is responsible for the other 10%.

Adrian Sanders, chair of the all-party parliamentary group for diabetes, claimed there was plenty of evidence out there to support Dr Rayman’s assessment.

He said the government was aware that a disproportionate number of people occupying hospital beds have diabetes, and their hospital stays are longer.

He said the government – and the last Labour administration – had encouraged more support for people with diabetes in primary care.

“That’s actually a very good policy for people whose condition doesn’t present complications or specialisms. And that’s why you need specialist care for those who present with specialist problems.”

Barbara Young, chief executive at Diabetes UK, said diabetes was a serious condition which could lead to devastating long term complications including blindness, kidney failure and amputations.

She said: “The tragedy is that for many people with diabetes, complications could have been avoided if the health checks were in place to spot any signs and if the appropriate care and treatment were applied.

“For example, up to 80% of amputation cases due to diabetes could be avoided if problems are identified early enough and treated appropriately.”

Personal responsibility

A key area of contention is whether diabetes is an issue for social or personal responsibility, with some arguing for tougher regulation of the food industry, whilst others argue healthy diet is strictly a matter for the individual.

Last week a ten-minute rule bill was introduced in the House of Commons by Keith Vaz arguing for the reduction of sugar content in soft drinks by 4%.

However, Paul McArdle, of the British Dietetic Association, cautioned against putting too much emphasis on sugar in food.

He said: “Food labelled ‘suitable for diabetics’ comes from the misguided principal that everything for people with diabetes is about sugar.

“The main focus for this group is losing weight and having a healthy diet, as this helps people with diabetes manage the condition.

“Around 60-90% of type two diabetes is caused by people being overweight, with more than half of that being preventable by having a healthy lifestyle.

“The bigger issue is good food labelling which can enable consumers of food to make healthy choices.”

Audit for improvement

The Department of Health issued a statement which accepted that good diabetes care was very important in hospital – and elsewhere.

“That is why the National Diabetes Inpatient Audit reviews diabetes management in hospital each year and feeds results back to individual hospitals to take appropriate action.

“NHS Diabetes is working with clinicians through their Inpatient Network to improve care.

“The Audit has already shown some improvements in care but more needs to be done.”

March 14, 2012 ~ Dr. Leonard Krivy Talks about Diabetes and Transplantation

Dr. Leonard Krivy is a nationally recognized educational consultant, author, broadcaster and newspaper columnist.  In his distinguished career, he’s been a teacher, career counselor, college dean, Director of Philadelphia’s Commission on Higher Education, Executive Director of the College of Allied Health Professions at Hahnemann Medical College, consultant and advisor on education to colleges, labor industry and government.

In recent years he has concentrated on individual counseling; specializing in guiding students to and through college; graduate and professional schools.

He offers unique expertise: detailed first-hand knowledge of educational systems and institutions; developed skills in advanced placement and counseling; and understanding of and an affinity for young people – a combination that affords and unduplicated personalized service.

Over the years, I’ve answered your questions on Schools and Schooling on CBS radio and in my newspaper columns.  I’ve met with numbers of you in my private educational counseling practice, where I specialize in high school; college, graduate and professional school advisement and placement, and in educational and vocational testing.  I also provide complete expert and confidential financial aid counseling for college, graduate and professional school.

For information on the wide range of educational and career planning services offered, or for an appointment, please call

Remember the right guidance is of lifelong importance.  I look forward to helping you.

1765 Fireside Lane
Cherry Hill, NJ  08003

Cherry Hill 856/428-1282
Philadelphia 215/545-1555

FAX 856/428-6910

Email: lpkphd@aol.com

Listen to Diabetes Living Today®

March 14, 2012 ~ Dr. Leonard Krivy Talks about Diabetes and Transplantation